Drug Profile
Research programme: AZM 090 - Alizyme
Alternative Names: AZM 090Latest Information Update: 01 Mar 2000
Price :
$50
*
At a glance
- Originator Alizyme
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity; Type 2 diabetes mellitus
Most Recent Events
- 01 Mar 2000 Discontinued-Preclinical for Obesity in United Kingdom (Unknown route)
- 01 Mar 2000 Discontinued-Preclinical for Type-2 diabetes mellitus in United Kingdom (Unknown route)
- 04 Jun 1997 Preclinical development for Obesity in United Kingdom (Unknown route)